Diop: There is an emphasis in India to be a significant part of global supply chains. There is also an opportunity to be a part of the semiconductor supply chain, as also in healthcare and pharmaceuticals, from traditional drugs to vaccines of the future, to genomics.
Over 20% of our portfolio here is in disruptive technology because we see an opportunity to combine the research and innovations in India with digitalization to play an important role in devising newer types of medicines that are more targeted, based on genomics, and tailored to diverse populations.
In India, we are looking at renewables. We will also look at frontier states. How we can help them to attract more private investments. We are very ambitious about India. We are looking to double our commitments to $1.3 to 2.5-3 billion over the next two years. India needs to continue investing in renewable energy supply chain, health, as well as logistics.
ET Interviewers: India will be taking over the presidency of the G20. What kind of agenda would you like to see?
